Core Viewpoint - The Shanghai Consumer Protection Committee has raised concerns regarding the authenticity of Antarctic krill oil products marketed by Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd, leading to an investigation and potential legal actions against the involved parties [4][5][9]. Group 1: Product Issues - A product labeled as "99% high-purity Antarctic krill oil" was found to have a phospholipid content of 0%, despite claims of 43% on its packaging [4][5]. - The product's marketing included misleading statements such as "high content," "imported from Chile," and "highly purified," which were proven to be false [5]. Group 2: Company Accountability - Anhui Hab Pharmaceutical Co., Ltd, the manufacturer, admitted that the product did not contain the claimed Antarctic krill oil during production [4][5]. - Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd, the distributor, denied knowledge of the alleged fraudulent activities and attempted to deflect responsibility [4][5]. Group 3: Regulatory Actions - The Shanghai Consumer Protection Committee has urged the distributor to conduct a self-examination, inform consumers of the situation, issue an apology, and recall the problematic products [5]. - The committee has also notified relevant regulatory authorities in Sichuan to monitor the situation [5]. Group 4: Company Background - Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd was established in June 2000 and is a member of the Beijing Tongrentang Group, with a 51% stake held by Beijing Tongrentang Health Pharmaceutical Co., Ltd [7][8]. - The company has faced scrutiny in the past for similar issues, including false advertising related to fish oil products [10].

Core Viewpoint - The Shanghai Consumer Protection Committee has taken action against a product labeled as "99% high-purity Antarctic krill oil" from Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., which was found to have misleading claims about its phospholipid content [2][5][6]. Group 1: Product Misrepresentation - The product in question claimed a phospholipid content of 43%, but testing revealed it contained none [5][6]. - The manufacturer, Anhui Hab Pharmaceutical Co., admitted that the product did not contain the advertised "Antarctic krill oil" during production [5][6]. Group 2: Corporate Responsibility - Beijing Tongrentang (Sichuan) Health Pharmaceutical Co. was urged to conduct a self-examination, apologize to consumers, and recall the problematic products [6]. - The company has stated that it will take legal action against the involved parties for unauthorized use of the "Beijing Tongrentang" name and to protect consumer rights [10]. Group 3: Regulatory Actions - The Shanghai Consumer Protection Committee has reported the issue to relevant regulatory authorities in Sichuan for further investigation [6]. - The incident highlights ongoing concerns regarding false advertising in health products, as previously reported by national media [12].

Core Viewpoint - The Shanghai Consumer Protection Commission has taken action against a product labeled as "99% high-purity Antarctic krill oil" from Beijing Tongrentang, revealing significant discrepancies between the product's claims and its actual content [1][4]. Group 1: Product Misrepresentation - A product marketed as having a phospholipid content of 43% was found to contain no actual Antarctic krill oil, indicating a serious misrepresentation [5]. - The product's promotional materials claimed high purity and quality, including statements like "1 capsule ≈ 100 krill," which were proven to be misleading [4][5]. Group 2: Company Accountability - The manufacturer, Anhui Habao Pharmaceutical Co., admitted that the product did not contain the advertised Antarctic krill oil and that the procurement price was significantly lower than normal [5]. - Beijing Tongrentang (Sichuan) Health Pharmaceutical Co. distanced itself from the issue during discussions, claiming ignorance of the alleged fraudulent activities [5][6]. Group 3: Regulatory Response - The Shanghai Consumer Protection Commission has urged Beijing Tongrentang (Sichuan) to conduct a self-examination, apologize to consumers, and recall the problematic products [6]. - The commission has also notified relevant regulatory authorities in Sichuan to monitor the situation closely [6]. Group 4: Legal Actions - Following the incident, Beijing Tongrentang Health Pharmaceutical Co. announced that it would take legal action against the involved parties for unauthorized use of its brand name and to protect consumer rights [11].